High-Density Lipoprotein-Targeted Therapies for Heart Failure

Area of Science:

• Cardiology
• Biochemistry
• Translational Medicine

Background:

• High-density lipoproteins (HDL) are complex particles composed of proteins, lipids, and microRNAs.
• HDL exhibits biochemical heterogeneity, contributing to its diverse functions.
• HDL's pleiotropic effects suggest potential therapeutic applications in heart failure.

Purpose of the Study:

• To explore the potential of HDL-targeted interventions for heart failure treatment.
• To investigate the direct effects of HDL on the myocardium, independent of coronary arteries.
• To evaluate HDL-targeted therapies in preclinical models of heart failure.

Main Methods:

• Analysis of HDL composition and biochemical heterogeneity.
• Murine studies investigating the effects of HDL on myocardial function.
• Assessment of HDL-targeted interventions in four distinct murine models of heart failure (HFrEF and HFpEF).

Main Results:

• HDL-targeted therapies demonstrated direct positive lusitropic effects on the myocardium.
• These interventions inhibited cardiac hypertrophy and suppressed myocardial fibrosis.
• HDL-targeted treatments increased myocardial capillary density and prevented heart failure in murine models, including both HFrEF and HFpEF.

Conclusions:

• HDL-targeted interventions show significant therapeutic potential for heart failure, acting directly on the myocardium.
• Preclinical studies support HDL-targeted therapies as a viable treatment strategy for both HFrEF and HFpEF.
• Clinical translation of HDL-targeted interventions is warranted, particularly for heart failure with preserved ejection fraction (HFpEF), addressing a critical unmet need.